Kymera Therapeutics (NASDAQ:KYMR) just reported results for the first quarter of 2024.
- Kymera Therapeutics reported earnings per share of -69 cents. This was above the analyst estimate for EPS of -73 cents.
- The company reported revenue of $10.29 million.
- This was 24.86% worse than the analyst estimate for revenue of $13.69 million.